Anti-HLA-A2 Alexa Fluor® 488

*Lee L, Loftus D, Appella E, Margulies DH, Mage M: A recombinant single-chain HLA-A2.1 molecule, with a cis active beta-2-microglobulin domain, is biologically active in peptide binding and antigen presentation. Hum Immunol. 1996 Aug;49 (1) :28-37., URL: https://www.ncbi.nlm.nih.gov/pubmed/8839773?ordina, *Forero L, Zwirner NW, Fink CW, Fernández-Viña MA, Stastny P: Juvenile arthritis, HLA-A2 and binding of DEK oncogene-peptides. Hum Immunol. 1998 Jul;59 (7) :443-50., URL: https://www.ncbi.nlm.nih.gov/pubmed/9684994?ordina, *Verdegaal EM, Huinink DB, Hoogstraten C, Marijnissen AK, Gorsira MB, Claas FH, Osanto S: Isolation of broadly reactive, tumor-specific, HLA Class-I restricted CTL from blood lymphocytes of a breast cancer patient. Hum Immunol. 1999 Dec;60 (12) :1195-206., URL: https://www.ncbi.nlm.nih.gov/pubmed/10626733?ordin, *Santin AD, Bellone S, Ravaggi A, Pecorelli S, Cannon MJ, Parham GP: Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells. Obstet Gynecol. 2000 Sep;96 (3) :422-30. , URL: https://www.ncbi.nlm.nih.gov/pubmed/10960637?ordin, *Liang B, Zhu L, Liang Z, Weng X, Lu X, Zhang C, Li H, Wu X: A simplified PCR-SSP method for HLA-A2 subtype in a population of Wuhan, China. Cell Mol Immunol. 2006 Dec;3 (6) :453-8., URL: https://www.ncbi.nlm.nih.gov/pubmed/17257499?ordin, *Santos-Aguado J, Barbosa JA, Biro PA, Strominger JL: Molecular characterization of serologic recognition sites in the human HLA-A2 molecule. J Immunol. 1988 Oct 15;141 (8) :2811-8.", URL: https://www.ncbi.nlm.nih.gov/pubmed/2459229?ordina, *Natali PG, Nicotra MR, Bigotti A, Venturo I, Marcenaro L, Giacomini P, Russo C: Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc Natl Acad Sci U S A. 1989 Sep;86 (17) :6719-23., URL: https://www.ncbi.nlm.nih.gov/pubmed/2672003?ordina, *Hogan KT, Brown SL: Localization and characterization of serologic epitopes on HLA-A2. Hum Immunol. 1992 Mar;33 (3) :185-92., URL: https://www.ncbi.nlm.nih.gov/pubmed/1377666?ordina, *Nijman HW, Houbiers JG, Vierboom MP, van der Burg SH, Drijfhout JW, D'Amaro J, Kenemans P, Melief CJ, Kast WM: Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur J Immunol. 1993 Jun;23 (6) :1215-9., URL: https://www.ncbi.nlm.nih.gov/pubmed/7684681?ordina, *Peoples GE, Goedegebuure PS, Andrews JV, Schoof DD, Eberlein TJ: HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer. J Immunol. 1993 Nov 15;151 (10) :5481-91. , URL: https://www.ncbi.nlm.nih.gov/pubmed/8228240?ordina, *Barouch D, Davenport M, McMichael A, Reay P: A mAb against HLA-A2 can be influenced both positively and negatively by the associated peptide. Int Immunol. 1995 Oct;7 (10) :1599-605., URL: https://www.ncbi.nlm.nih.gov/pubmed/8562505?ordina, *Scornik JC: HLA-A2 epitopes recognized by alloantibodies from broadly sensitized patients. Hum Immunol. 1987 Apr;18 (4) :277-85., URL: https://www.ncbi.nlm.nih.gov/pubmed/2437089?ordina

The antibody BB7.2 recognizes an extracellular epitope at the C-terminus of alpha-2 helix and a turn on one of the underlying beta strands within the human HLA-A2 histocompatibility antigen.